Patent classifications
C07C59/255
PROCESS FOR THE PREPARATION OF CYSTEAMINE BITARTRATE AND PRODUCT SO OBTAINED
The present invention relates to a new, enhanced process for the manufacture of Cysteamine Bitartrate (I) and of its key intermediate thiazolidine (II).
Furthermore, it relates to a new processes for the manufacture of crystalline anhydrous Cysteamine Bitartrate (polymorph L2) and monohydrate Cysteamine Bitartrate (polymorph L1). The crystalline anhydrous Cysteamine Bitartrate (polymorph L2) so obtained is characterized by particularly fine particle size and good appearance.
SALT AND CRYSTAL FORMS OF 4-AMINO-5-(6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZO[D]IMIDAZOL-2-YL)THIENO[2,3-B]PYRIDIN-6(7H)-ONE
A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed. (I), Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.
##STR00001##
SALT AND CRYSTAL FORMS OF 4-AMINO-5-(6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZO[D]IMIDAZOL-2-YL)THIENO[2,3-B]PYRIDIN-6(7H)-ONE
A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed. (I), Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.
##STR00001##
AXL KINASE INHIBITORS AND USE OF THE SAME
Tartrate salts of the compound of structure (I),
##STR00001##
, crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN
The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.
##STR00001##
FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN
The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.
##STR00001##
PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR
The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
L-tartrate salt of pridopidine
The subject invention provides pridopidine L-tartrate, compositions and a process for manufacture thereof.
L-tartrate salt of pridopidine
The subject invention provides pridopidine L-tartrate, compositions and a process for manufacture thereof.
L-tartrate salt of pridopidine
The subject invention provides pridopidine L-tartrate, compositions and a process for manufacture thereof.